Short answer
Trevi Therapeutics, Inc. (TRVI) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$13M
- −27.6% YoY
- EPS (diluted)
- −$0.09
- +0.0% YoY
Source: XBRL data from the Trevi Therapeutics, Inc. (TRVI) Q1 2026 10-Q on SEC EDGAR. USD.
Trevi Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; net loss $13.2M vs $10.3M YoY
- R&D expenses $9.9M vs $7.8M; G&A $5.0M vs $3.7M YoY
- Cash, equivalents and marketable securities $171.8M as of March 31, 2026
- Operating cash outflow $16.7M vs $13.5M YoY
- April 2026 Offering net proceeds approximately $162M; Phase 3 IPF trials planned for 2026
Risk Factors
- No Risk Factors section provided; substantive risk changes cannot be assessed
- New insider trading arrangement: Chief Scientific Officer plan adopted January 21, 2026, covering up to 3,947 shares
- Trading-plan expiration: December 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Trevi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.